174610-12-9

Basic information

• Product Name: 1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI)
• Synonyms: 1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI);1H-Pyrrolo[2,3-c]pyridin-5-amine;5-AMino-6-azaindole
• CAS NO: 174610-12-9
• Molecular Formula: C₇H₇N₃
• Molecular Weight: 133.15
• EINECS: 145-896-5
• Product Categories: PYRIDINE
• Mol File: 174610-12-9.mol

Chemical Properties

• Boiling Point: 388.5 °C at 760 mmHg
• Flash Point: 217.1 °C
• Appearance: /
• Density: 1.367 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 15.05±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI)(174610-12-9)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI)(174610-12-9)

Safety Data

• Hazardous Substances Data: 174610-12-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI) is used as a key intermediate in the synthesis of pharmaceutical compounds for its ability to form pyridine-containing molecules. These pyridine-cored compounds are often found in drugs targeting a wide range of therapeutic areas, including but not limited to cardiovascular, neurological, and oncological applications.
The specific uses of 1H-Pyrrolo[2,3-c]pyridin-5-amine(9CI) in the pharmaceutical industry are centered around its role in creating complex molecular structures that can interact with biological targets, such as enzymes, receptors, or ion channels, to elicit desired pharmacological effects. Its presence in the final drug molecules can contribute to properties like potency, selectivity, and pharmacokinetics, which are crucial for the drug's efficacy and safety profile.

Upstream product

• 960505-80-0 C₉H₁₂N₄O₂ 
• 90765-02-9 N-(4-methyl-5-nitropyridin-2-yl) acetamide 
• 174610-11-8 N-(1H-pyrrolo[2,3-c]pyridin-5-yl)acetamide 

Relevant articles and documents

A convenient synthesis of linear pyridinoimidazo[1,2-a]pyridine and pyrroloimidazo[1,2-a]pyridine cores

Two new imidazo[1,2-a]pyridine derivatives, pyridinoimidazo[1,2-a]pyridine (10) and pyrroloimidazo[1,2-a]pyridine (16), were synthesised from 2-amino-4-methyl-5-nitropyridine (1) by linear cyclisation, making use of dimethylformamide dimethylacetal (DMFDMA) as an agent of vinylamine functionalisation. This report describes first the formation of pyridine and pyrroloimidazopyridine from (1), and then the formation of pyridine-fused and pyrrolo-fused pyridine by the Friedl?nder method and reductive cyclisation followed by treatment of the resulting adduct with chloroacetaldehyde.

Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists

Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R2 ; V represents oxygen, sulphur or N--R3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH=C--; R1 represents C3-6 alkenyl, C3-6 alkynyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; and R2 and R3 independently represent hydrogen or C1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.